Having observed induction of intra-spheroid steatosis and accumulation of triglycerides with a consequent increase of COL1A1 levels, we next investigated whether this intra-spheroid steatosis could be prevented by using four compounds for the treatment of NASH, namely liraglutide, elafibranor, vitamin E and obeticholic acid. This evidence concerns the gene COL1A1 and metabolic dysfunction-associated steatohepatitis.